Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 1

Status

Unknown 4Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Stomach Neoplasms 56Carcinoma, Hepatocellular 43Carcinoma, Non-Small-Cell Lung 23Small Cell Lung Carcinoma 19Ovarian Neoplasms 18Colorectal Neoplasms 18Breast Neoplasms 17Sarcoma 14Neoplasms 14Triple Negative Breast Neoplasms 13Nasopharyngeal Carcinoma 11Esophageal Squamous Cell Carcinoma 10Cholangiocarcinoma 10Osteosarcoma 9Lung Neoplasms 9Esophageal Neoplasms 9Neoplasm Metastasis 8Biliary Tract Neoplasms 8Advanced Gastric Cancer 8Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Recurrence 6Pancreatic Neoplasms 6Head and Neck Neoplasms 6Thyroid Neoplasms 4Solid Tumor 4Melanoma 4Liver Neoplasms 4Glioma 4Drug-Related Side Effects and Adverse Reactions 4

Interventions

Gemcitabine 679130-nm albumin-bound paclitaxel 198Fluorouracil 186Oxaliplatin 175Albumin-Bound Paclitaxel 151Capecitabine 137Leucovorin 131Irinotecan 113Radiotherapy 95Taxes 83pembrolizumab 80Cisplatin 72Erlotinib Hydrochloride 69Radiosurgery 67Nivolumab 56Bevacizumab 54Drug Therapy 52Cyclophosphamide 49Magnetic Resonance Spectroscopy 46folfirinox 42Docetaxel 41Cetuximab 40Specimen Handling 37irinotecan sucrosofate 36S 1 (combination) 36Biopsy 31Radiation 29Paclitaxel 29Ipilimumab 27durvalumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Pancreatic Neoplasms × apatinib × Clear all
NCT04581473 2025-06-05

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

CARsgen Therapeutics Co., Ltd.

Phase 1/2 Active not recruiting
192 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms

NCT06759090 2025-01-06

Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

Zhejiang University

Phase 2 Not yet recruiting
43 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04415385 2020-06-04

The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma

Zhejiang Cancer Hospital

Phase 2 Unknown
48 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04101929 2019-11-05

Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen

Fudan University

Phase 2 Unknown
126 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02726854 2016-12-02

Apslpanc

First Affiliated Hospital Xi'an Jiaotong University

Phase 2 Unknown
30 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02863367 2016-08-11

OECTAPGAMPC

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡